ArticleCancer medicine2023

Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.

Yuqin Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.